Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly Partners with Sosei Heptares on GPCR Targets | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Lilly Partners with Sosei Heptares on GPCR Targets

The potential $730 million collaboration will leverage Sosei’s StaR platform and Lilly’s expertise in diabetes and metabolic diseases.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eli Lilly and Co. has entered a collaboration agreement with Sosei Heptares to develop small molecules that modulate G protein-coupled receptor (GPCR) targets in diabetes and metabolic diseases.
 
Under the collaboration, Lilly will pay $37 million upfront and Sosei is eligible to receive as much as $694 million in development and commercial milestones, as well as royalties.
 
The collaboration will leverage Sosei’s StaR platform, which designs GPCRs by engineering a small number of single point mutations, and Lilly’s expertise in diabetes and metabolic diseases. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics